With a deep background in biopharmaceutical research and development, Ivan Kairatov has a keen eye
The emergence of cell-cultured protein has sparked intense debate at the intersection of
We're joined today by Biopharma expert Ivan Kairatov, whose work sits at the intersection of technology and research and development. We'll be discussing groundbreaking new research that is shattering the long-held, simplistic view of the vaginal microbiome. This conversation will explore how a
The immense complexity of the human brain, mirrored in the subtle and highly variable details of magnetic resonance images, has long presented a formidable challenge for both clinicians and researchers striving for earlier and more accurate diagnoses of neurological conditions. A groundbreaking AI
The quest for a single, reliable signal to detect cancer in its infancy has long been the holy
For individuals grappling with the relentless and often disfiguring effects of cutaneous lupus
The biopharmaceutical sector is entering a new era. After last year's market disruptions, the industry faces a harsh truth: scientific breakthroughs alone are no longer enough to keep ahead of the…
By 2030, the tissue-engineering market is projected to exceed $32.45 billion , reflecting a
The landscape of rare disease drug development is littered with clinical failures. For every
Major policy changes are colliding with the complex economics of drug development. For B2B
Biopharma companies have always operated at the edge of uncertainty. Scientific discovery is
The burgeoning market for GLP-1 weight-loss medications created a gold rush for telehealth companies, but for Hims & Hers, a bold move into this lucrative space has rapidly devolved into a multi-front battle with regulators and pharmaceutical giants. The company's recent announcement that it would
Today we’re speaking with Ivan Kairatov, a biopharma expert with a deep understanding of how
The quiet aftermath of a traumatic event often conjures images of panicked awakenings and a
